nature portfolio

| Corresponding author(s): | Jack Hu, Mark Lawrence, Jennifer Dionne |
|----------------------------|---|
| Last updated by author(s): | Apr 23, 2023 |

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

| Statistics |
|---|
| For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
| n/a Confirmed |
| The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. |
| A description of all covariates tested |
| A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable. |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |
| Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |
| |

Software and code

Policy information about availability of computer code

Data collection

Lightfield (Teledyne version 6.15.2.2201)

Data analysis

Numerical simulations of metasurfaces performed with Lumerical FDTD (2021 R2.5). Computations and analysis were carried out in Matlab 2017b. DNA probe optimization performed with mfold (ver 3.0).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data that support the findings of this study is deposited to Zenodo with the access link: 10.5281/zenodo.7827159

| Research inv | olving hui | man participants, their data, or biological material | |
|---|---|---|--|
| Policy information a and sexual orientat | | ith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation), chnicity and racism</u> . | |
| Reporting on sex | and gender | N/A | |
| Reporting on race other socially rele groupings | | N/A | |
| Population chara | cteristics | N/A | |
| Recruitment | | N/A | |
| Ethics oversight | | N/A | |
| Note that full informa | ition on the appro | oval of the study protocol must also be provided in the manuscript. | |
| Field-spe | cific re | porting | |
| Please select the or | ne below that is | the best fit for your research. If you are not sure, read the appropriate sections before making your selection. | |
| Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences | | | |
| For a reference copy of t | he document with a | all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u> | |
| Life scier | nces stu | ıdy design | |
| All studies must dis | close on these | points even when the disclosure is negative. | |
| Sample size | DNA binding measurements were performed with synthetically synthesized nucleic acid materials and sample sizes were based on individual sensing devices as stated in the main text and figures. | | |
| Data exclusions | No data were ex | ere excluded. | |
| Replication | | cid binding experiments were reproducible and measured across a large number of individual sensing devices. Data from all asors are included in the paper. | |
| Randomization | | omization was used because the studies utilized synthetically synthesized nucleic acid samples to demonstrate sensor performance can comparing clinical samples. Nasopharyngeal swab specimens were pooled to provide a background matrix for synthetic target in. | |
| Blinding | Blinding was no | t applicable to this study as nucleic targets were from synthetically synthesized materials. | |
| We require information system or method list | on from authors a red is relevant to | Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. | |
| Materials & exp | | | |
| n/a Involved in the study | | ChIP-seq Flow cytometry | |
| Animals and other organisms | | | |
| Clinical data Dual use research of concern | | | |
| Plants | | | |